NO20005757L - Cabergolin og pramipexol - nye anvendelser og kombinasjoner - Google Patents
Cabergolin og pramipexol - nye anvendelser og kombinasjonerInfo
- Publication number
- NO20005757L NO20005757L NO20005757A NO20005757A NO20005757L NO 20005757 L NO20005757 L NO 20005757L NO 20005757 A NO20005757 A NO 20005757A NO 20005757 A NO20005757 A NO 20005757A NO 20005757 L NO20005757 L NO 20005757L
- Authority
- NO
- Norway
- Prior art keywords
- cabergoline
- pramipexole
- combinations
- treatment
- new uses
- Prior art date
Links
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title abstract 5
- 229960004596 cabergoline Drugs 0.000 title abstract 5
- 229960003089 pramipexole Drugs 0.000 title abstract 5
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8561998P | 1998-05-15 | 1998-05-15 | |
| US8794398P | 1998-06-04 | 1998-06-04 | |
| PCT/US1999/007024 WO1999059563A2 (fr) | 1998-05-15 | 1999-05-07 | Cabergoline et pramipexole: nouvelles utilisations et combinaisons |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20005757D0 NO20005757D0 (no) | 2000-11-14 |
| NO20005757L true NO20005757L (no) | 2000-11-14 |
Family
ID=26772918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005757A NO20005757L (no) | 1998-05-15 | 2000-11-14 | Cabergolin og pramipexol - nye anvendelser og kombinasjoner |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6503920B1 (fr) |
| EP (1) | EP1076559B1 (fr) |
| JP (1) | JP2002515425A (fr) |
| KR (3) | KR20060056416A (fr) |
| CN (1) | CN1301159A (fr) |
| AT (1) | ATE310517T1 (fr) |
| AU (1) | AU748629B2 (fr) |
| BR (1) | BR9909917A (fr) |
| CA (1) | CA2327299A1 (fr) |
| DE (1) | DE69928521T2 (fr) |
| DK (1) | DK1076559T3 (fr) |
| EA (4) | EA200200955A1 (fr) |
| ES (1) | ES2251191T3 (fr) |
| HU (1) | HUP0101803A3 (fr) |
| IL (1) | IL139682A0 (fr) |
| NO (1) | NO20005757L (fr) |
| NZ (2) | NZ526071A (fr) |
| PL (1) | PL344574A1 (fr) |
| SG (1) | SG121745A1 (fr) |
| SK (1) | SK16272000A3 (fr) |
| TR (1) | TR200003356T2 (fr) |
| WO (1) | WO1999059563A2 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0007309D0 (en) | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10138275A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
| DE10148233A1 (de) * | 2001-09-28 | 2003-04-10 | Boehringer Ingelheim Pharma | Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme |
| PA8578501A1 (es) | 2002-07-25 | 2005-02-04 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
| GB0221513D0 (en) * | 2002-09-17 | 2002-10-23 | Generics Uk Ltd | Novel compounds and processes |
| EP2431026A1 (fr) | 2004-08-13 | 2012-03-21 | Boehringer Ingelheim International GmbH | Formulation de pastille à libération prolongée contenant du pramipexole ou l'un de ses sels pharmaceutiquement acceptable, son procédé de fabrication et utilisation associée |
| ES2355735T5 (es) | 2004-08-13 | 2014-06-27 | Boehringer Ingelheim International Gmbh | Formulación en comprimidos de liberación extendida que contiene pramipexol o una de sus sales farmac�uticamente aceptables, método para su fabricación y su uso |
| EP1988875A2 (fr) * | 2006-02-10 | 2008-11-12 | Boehringer Ingelheim International GmbH | Formulation a liberation modifiee |
| PL232974B1 (pl) * | 2015-12-09 | 2019-08-30 | Ofta Spolka Z Ograniczona Odpowiedzialnoscia | Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| DE3937271A1 (de) * | 1989-11-09 | 1991-05-16 | Boehringer Ingelheim Kg | Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol |
| WO1995005176A1 (fr) * | 1993-08-18 | 1995-02-23 | Alcon Laboratories, Inc. | Derives de l'ergoline pour le traitement du glaucome |
| US5496836A (en) * | 1994-05-05 | 1996-03-05 | Mount Sinai School Of Medicine Of The City University Of New York | Use of famotidine and related compounds in the treatment of movement disorders |
| US5650420A (en) * | 1994-12-15 | 1997-07-22 | Pharmacia & Upjohn Company | Pramipexole as a neuroprotective agent |
| FR2728374A1 (fr) * | 1994-12-15 | 1996-06-21 | Aerospatiale | Procede et dispositif pour fournir une information, alerte ou alarme pour un aeronef a proximite du sol |
-
1999
- 1999-05-07 DE DE69928521T patent/DE69928521T2/de not_active Expired - Fee Related
- 1999-05-07 HU HU0101803A patent/HUP0101803A3/hu unknown
- 1999-05-07 TR TR2000/03356T patent/TR200003356T2/xx unknown
- 1999-05-07 ES ES99919772T patent/ES2251191T3/es not_active Expired - Lifetime
- 1999-05-07 EA EA200200955A patent/EA200200955A1/ru unknown
- 1999-05-07 CA CA002327299A patent/CA2327299A1/fr not_active Abandoned
- 1999-05-07 SG SG200206791A patent/SG121745A1/en unknown
- 1999-05-07 EA EA200300124A patent/EA200300124A1/ru unknown
- 1999-05-07 CN CN99805219A patent/CN1301159A/zh active Pending
- 1999-05-07 JP JP2000549228A patent/JP2002515425A/ja active Pending
- 1999-05-07 WO PCT/US1999/007024 patent/WO1999059563A2/fr not_active Ceased
- 1999-05-07 DK DK99919772T patent/DK1076559T3/da active
- 1999-05-07 IL IL13968299A patent/IL139682A0/xx unknown
- 1999-05-07 AT AT99919772T patent/ATE310517T1/de not_active IP Right Cessation
- 1999-05-07 NZ NZ526071A patent/NZ526071A/en unknown
- 1999-05-07 AU AU37419/99A patent/AU748629B2/en not_active Ceased
- 1999-05-07 EA EA200001192A patent/EA004474B1/ru not_active IP Right Cessation
- 1999-05-07 US US09/674,838 patent/US6503920B1/en not_active Expired - Fee Related
- 1999-05-07 KR KR1020067007719A patent/KR20060056416A/ko not_active Ceased
- 1999-05-07 SK SK1627-2000A patent/SK16272000A3/sk unknown
- 1999-05-07 BR BR9909917-9A patent/BR9909917A/pt not_active Application Discontinuation
- 1999-05-07 NZ NZ508184A patent/NZ508184A/en unknown
- 1999-05-07 EP EP99919772A patent/EP1076559B1/fr not_active Expired - Lifetime
- 1999-05-07 EA EA200300125A patent/EA200300125A1/ru unknown
- 1999-05-07 KR KR1020067007720A patent/KR20060056417A/ko not_active Ceased
- 1999-05-07 KR KR1020007012760A patent/KR20010043612A/ko not_active Ceased
- 1999-05-07 PL PL99344574A patent/PL344574A1/xx not_active IP Right Cessation
-
2000
- 2000-11-14 NO NO20005757A patent/NO20005757L/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1137762T3 (da) | Behandling af Pompes sygdom | |
| TW200509968A (en) | Prevention and treatment of synucleinopathic disease | |
| NO20071267L (no) | Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer | |
| ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
| DK0723444T3 (da) | Levobupivacain, som er egnet til behandling af kronisk smerte | |
| DK1632483T3 (da) | Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin-D3-receptorligander | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
| NO20005757D0 (no) | Cabergolin og pramipexol - nye anvendelser og kombinasjoner | |
| PT912184E (pt) | Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina | |
| FR2777781B1 (fr) | Associations riluzole et l-dopa pour le traitement de la maladie de parkinson | |
| NZ504419A (en) | The use of carvedilol for treating amyloid diseases such as Alzheimer's | |
| GB0020504D0 (en) | Therapeutic method | |
| DK1392676T3 (da) | Hidtil ukendte heterocykliske urinstofderivater og deres anvendelse som dopamin -D3 - receptorligander | |
| MY124071A (en) | Treatment of viral disease in swine | |
| DK1244438T3 (da) | Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde | |
| BR0113646A (pt) | Tratamento de distúrbios inflamatórios | |
| MXPA01007952A (es) | Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas. | |
| PT1304107E (pt) | Utilizacao de derivados de oxazolidininas para o tratamento da psoriase | |
| MX9503363A (es) | N-(2,6-dioxo-3-piperidil) ftalimida (generico talidomida como tratamiento del sindrome de desgaste asociado con la infeccion por vih-1. | |
| EA200001091A1 (ru) | Способ лечения заболеваний, связанных с образованием конкрементов | |
| UA42274A (uk) | Спосіб профілактики та лікування функціональних розладів організму пацієнта | |
| UA23921A (uk) | Спосіб лікування шлунково-стравохідного рефлюксу |